Nevertheless, the addition of these studies does not change the performance results shared in this literature review, as the best panels remain for both bladder cancer (with 100% sensitivity and specificity for the SOX1, TJP2, MYOD, HOXA9_1, HOXA9_2 panel [12]) and CRC (with a sensitivity of 98% and a specificity of 90% for the BMP3 and NDRG4 panel [18]). This evidence concerns the gene MYOD1 and colorectal carcinoma.